PMI PMI
Company Profile ↓Company Overview
PMI (PMI) is a publicly traded company listed on with a market capitalization of $267.54M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $4.94M (+12.5% YoY); net profit $-27.00M.
- Trailing 12 Months Year-on-year growth — revenue +12.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.30% |
| 1 Year: | 12.50% |
Stock Price Performance
| 1 Year: | -98.42% |
| 6 Months: | -96.22% |
| 3 Months: | -65.43% |
| 1 Month: | -56.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 881.00K | - | 620.00K | 2.13M | 1.19M | 1.01M | 1.15M |
| Cost of Revenue | - | - | - | - | 978.00K | 2.26M | 1.32M | 598.00K | 875.00K |
| Gross Profit | - | -382.00K | -673.00K | - | -358.00K | -127.00K | -130.00K | 411.00K | 275.00K |
| Operating Expenses | - | - | - | - | 2.89M | 3.39M | 3.36M | 3.41M | 4.79M |
| Operating Income | - | -3.82M | -4.44M | - | -3.25M | -3.52M | -3.49M | -3.00M | -4.51M |
| EBITDA | - | - | - | - | -4.85M | -4.17M | -7.89M | -4.15M | -7.47M |
| Interest Expense | - | - | - | - | 555.00K | 2.43M | 2.40M | 7.00K | 5.00K |
| Pretax Income | - | - | - | - | -5.53M | -6.72M | -10.43M | -4.29M | -7.62M |
| Tax Provision | - | - | - | - | 31.00K | 0 | 0 | 4.00K | 0 |
| Net Income | -1.95M | -4.06M | -6.21M | - | -5.56M | -6.72M | -10.43M | -4.29M | -7.62M |
| Diluted EPS | - | - | - | - | -0.09 | -0.10 | -0.19 | - | -0.10 |
| R&D Expense | - | 940.00K | 961.00K | - | 808.00K | 743.00K | 951.00K | - | 1.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 4.11M | 5.04M | 4.39M | 4.94M |
| Cost of Revenue | 9.10M | 7.35M | 4.50M | 5.14M |
| Gross Profit | -4.99M | -2.31M | -112.00K | -204.00K |
| Operating Expenses | 6.08M | 13.19M | 13.60M | 13.05M |
| Operating Income | -11.07M | -15.50M | -13.71M | -13.26M |
| EBITDA | -10.61M | -14.85M | -17.46M | -21.06M |
| Interest Expense | 5.00K | 140.00K | 3.07M | 5.39M |
| Pretax Income | -11.16M | -15.57M | -21.07M | -26.97M |
| Tax Provision | 11.00K | -2.00K | -15.00K | 35.00K |
| Net Income | -11.17M | -15.57M | -21.05M | -27.00M |
| Diluted EPS | -0.18 | -0.25 | -0.33 | -0.75 |
| R&D Expense | - | - | 3.38M | 3.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 15.44M | 11.37M | 12.11M | 22.55M |
| Current Assets | 12.12M | 8.76M | 9.79M | 20.73M |
| Cash & Equivalents | 152.00K | 244.00K | 96.00K | 7.45M |
| Inventory | 7.33M | 6.89M | 8.12M | 7.30M |
| Receivables | 882.00K | 629.00K | 513.00K | 623.00K |
| Total Liabilities | 4.07M | 14.93M | 35.84M | 18.76M |
| Current Liabilities | 3.00M | 9.21M | 35.33M | 18.70M |
| Long Term Debt | - | 4.28M | - | - |
| Total Debt | 1.96M | 9.41M | 20.93M | 6.97M |
| Total Equity | 11.37M | -3.55M | -23.74M | 3.79M |
| Shares Outstanding | 72.06M | 72.06M | 72.06M | 73.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -10.72M | -10.63M | -11.87M | -15.67M |
| Investing Cash Flow | -37.00K | -9.00K | 0 | 0 |
| Financing Cash Flow | 5.52M | 10.84M | 11.74M | 27.08M |
| Capital Expenditure | -29.00K | -7.00K | - | - |
| Free Cash Flow | -10.75M | -10.64M | -11.87M | -15.67M |
| Net Change in Cash | -5.24M | 197.00K | -133.00K | 11.40M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | -121.3% | -45.8% | -2.6% | -4.1% |
| Operating Margin % | -269.1% | -307.4% | -312.3% | -268.4% |
| Net Margin % | -271.5% | -308.7% | -479.5% | -546.6% |
| ROE % | -98.2% | 438.3% | 88.7% | -712.6% |
| ROCE % | -89.0% | -717.0% | 59.1% | -344.1% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PMI
Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026
–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform–TUCSON, Ariz., July 31, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (N…
Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026
-First scientific presentation of the Emperor Drive System architecture to the biomedical engineering community- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the "Company"), parent …
Picard Medical Receives NYSE American Acceptance of Compliance Plan
-Company continues advancing long-term growth strategy under accepted compliance plan-TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardi…
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
-Reverse stock split to support continued compliance with NYSE American continued listing standards- TUCSON, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company" or "Picard Medical"), parent comp…
Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program
Peer-reviewed journal's News section highlights the Company’s continued progress toward a fully implantable total artificial heartTUCSON, Ariz., July 15, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” o…
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder ConsiderationTUCSON, Ariz., July 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard Medical" or the "Company…
PMI — Frequently Asked Questions
What is the current share price of PMI?
As of 2026-08-05 17:25 PDT, PMI trades at $3.63 on NASDAQ/NYSE. Its 52-week range is $3.63 to $660.00.
What is the market capitalisation of PMI?
PMI has a market capitalisation of $267.54M on NASDAQ/NYSE.
What is the P/E ratio of PMI?
PMI trades at a trailing price-to-earnings (P/E) ratio of -4.84. Its price-to-book (P/B) ratio is 70.62.
Is PMI a good stock to buy?
This page provides a data-driven analysis of PMI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.